Peking University 3rd Hospital
Beijing, Beijing Municipality, 100191, China
Location status: Recruiting
Location contact
Li Yunfeng, MD
SUB_INVESTIGATOR
Zhang Long, MD
CONTACT
82266699 ext. 010
Zhang Long, MD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT06841237
Diabetes is one of the major chronic diseases. Diabetic ulcers are important adverse outcomes of diabetes. Approximately 80% of lower - limb amputations are caused by diabetic foot ulcers, which are the main causes of disability and death among patients. Moreover, it places a huge burden on the medical insurance system. Currently, there are western medicine treatment guidelines for diabetic foot, yet the clinical efficacy is less than satisfactory. The amputation rate caused by diabetic foot ulcers continues to rise every year. There is an urgent clinical need for novel and effective intervention measures to address this disease.
Macrophages are important cells involved in the inflammatory and proliferative phases of wounds, playing a crucial role in wound repair and reconstruction. Diabetes can cause wounds to remain in the pro - inflammatory stage continuously, leading to the aggregation of M1 macrophages and preventing their timely transformation into the pro - proliferative and repair stage. As a result, wounds exhibit persistent chronic inflammation and delayed tissue proliferation or remodeling.
Xianglei Tangzu Ointment is a natural medicine approved for marketing by the National Medical Products Administration in November 2023. Its ingredients include Pogostemon cablin extract and asiaticoside. Research shows that the plant components in Xianglei Tangzu Ointment can promote the transformation of M1 macrophages into M2 macrophages, thereby reducing the inflammatory response and accelerating the proliferative repair of diabetic wounds. It has achieved certain curative effects in the clinical treatment of promoting wound healing. In order to use Xianglei Tangzu Ointment more precisely, accumulate clinical evidence - based medicine evidence, and explore the effectiveness and safety of Xianglei Tangzu Ointment in treating diabetic ulcers under the guidance of the chronic wound staging theory, clinical evidence - based medicine evidence needs to be obtained.
Interested in participating?
Request Info18 year–80 year
All sexes
Interventional
Not applicable
Beijing, Beijing Municipality, 100191, China
Location status: Recruiting
Li Yunfeng, MD
SUB_INVESTIGATOR
Zhang Long, MD
CONTACT
82266699 ext. 010
Zhang Long, MD
PRINCIPAL_INVESTIGATOR
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A therapy for chronic wound healing
A therapy for chronic wound healing
Time frame: From enrollment to the end of treatment at 2 weeks
Pre-treatment area minus post-treatment area, then divided by pre-treatment area
Time frame: From enrollment to the end of treatment at 3 weeks
Percentage of healed wounds to total cases by D21
Time frame: From enrollment to the end of treatment at 3 weeks
They were classified as healthy granulation, inflammatory granulation, infected granulation, oedematous granulation, and aged granulation. D0/D14/D21, wound granulation tissue status was recorded separately
Time frame: From enrollment to the end of treatment at 3 weeks
0 points for no infection, 1 point for reduction of localised infection; 2 points for maintenance or exacerbation of localised infection; 3 points for disseminated infection; record D0/D14/D21, the status of the wound infection and record the scoring results respectively
Peking University Third Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07493343
Cardiovascular Diseases, Diabetes Complications
Lahore, Punjab Province, Pakistan
View Trial DetailsNCT06565156
Cardiovascular Diseases, Diabetes Complications
Guntersville, Alabama, United States
View Trial DetailsNCT07258381
Chronic Wound Care, Diabetic Wound
View Trial DetailsNCT06608303
Diabetic Wound
Beijing, Beijing Municipality, China
View Trial Details